Holen Sie sich die Stockscreener-App
30.78
0.06%
-0.02
Handel nachbörslich:
30.78
Schlusskurs vom Vortag:
$30.80
Offen:
$30.54
24-Stunden-Volumen:
1.06M
Relative Volume:
0.96
Marktkapitalisierung:
$2.91B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-22.97
EPS:
-1.34
Netto-Cashflow:
$-104.72M
1W Leistung:
+11.44%
1M Leistung:
-3.66%
6M Leistung:
+83.11%
1J Leistung:
+261.69%
1-Tages-Spanne:
$30.06
$32.61
1-Wochen-Bereich:
$28.00
$35.50
52-Wochen-Spanne:
$8.64
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
30.78 | 2.91B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by State Street Corp - MarketBeat
What is Leerink Partnrs’ Forecast for EWTX FY2026 Earnings? - Defense World
Leerink Partnrs Has Strong Estimate for EWTX FY2026 Earnings - MarketBeat
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 10.2% - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
EWTX Stock Rises On Upbeat Data From Rare Muscular Disorder Study - Barchart
Wellington Management Group LLP Sells 288,526 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - AOL
Edgewise Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Edgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Edgewise weighs fast approval path for muscular dystrophy drug - BioPharma Dive
Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News - Stocks Telegraph
Edgewise Therapeutics Shares Higher on Positive Trial Results - MarketWatch
Edgewise rises on mid-stage trial results for muscular dystrophy candidate - Seeking Alpha
Edgewise Therapeutics Shares Surge 21% on Positive Phase 2 CANYON Trial Results for Becker Muscular Dystrophy Drug - mediahousepress
Edgewise Therapeutics shares surge on positive trial results By Investing.com - Investing.com Australia
Edgewise Therapeutics shares surge on positive trial results - Investing.com India
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Edgewise's Muscular Dystrophy Drug Shows Promising 28% Reduction in Muscle Damage in Phase 2 Trial - StockTitan
Trading (EWTX) With Integrated Risk Controls - Stock Traders Daily
Edgewise distances from researcher criticized by FDA - BizWest
28,303 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by XTX Topco Ltd - MarketBeat
Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma - Barchart
Hypertrophic Cardiomyopathy Market Forecasted to Surge - openPR
Fmr LLC Sells 4,127,355 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Frazier Life Sciences Management L.P. - MarketBeat
Charles Schwab Investment Management Inc. Sells 49,111 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Data-Based Insights About Edgewise Therapeutics Inc (EWTX) - Stocks Register
Edgewise confirms FDA compliance amid warning to researcher By Investing.com - Investing.com Canada
Truist maintains Buy on Edgewise Therapeutics, holds $50 target By Investing.com - Investing.com Canada
Edgewise confirms FDA compliance amid warning to researcher - Investing.com
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research - Business Wire
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Glenmede Trust Co. NA Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics' SWOT analysis: biotech stock poised for growth amid clinical milestones - Investing.com Australia
Parkman Healthcare Partners LLC Has $17.54 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
How the (EWTX) price action is used to our Advantage - Stock Traders Daily
HighVista Strategies LLC Makes New $2.37 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
21,128 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Fred Alger Management LLC - MarketBeat
19,900 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Intech Investment Management LLC - MarketBeat
Walleye Capital LLC Purchases New Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Braidwell LP Purchases Shares of 1,958,310 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
Ally Bridge Group NY LLC Buys Shares of 187,695 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Acuta Capital Partners LLC Buys Shares of 63,000 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics shares target lifted, buy rating on positive outlook By Investing.com - Investing.com UK
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 - BioSpace
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Option Exercise |
0.18 |
75,000 |
13,500 |
87,719 |
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Sale |
28.27 |
75,000 |
2,120,101 |
12,719 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Option Exercise |
0.71 |
50,000 |
35,500 |
53,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Option Exercise |
0.71 |
20,922 |
14,855 |
24,174 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Sale |
28.37 |
50,000 |
1,418,510 |
3,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Sale |
27.63 |
20,922 |
578,064 |
3,252 |
| Donovan Joanne M. | CMO |
Sep 20 '24 |
Sale |
28.29 |
7,162 |
202,603 |
14,538 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
42,068 |
81,191 |
57,189 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Sale |
29.03 |
42,068 |
1,221,133 |
15,121 |
| Carruthers R Michael | Chief Financial Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
96,068 |
185,411 |
81,996 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):